Filgotinib

Red

Brand Name(s):

Indication:Moderate to severe Rheumatoid Artritis in Adults

Rationale:1,2

Considered:Mar-21

Review Date:Mar-26

Comments:
NICE TA676 February 21:
NICE recommends filgotinib for moderate to severe RA in adults if specific criteria met as described in the guidance:
Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), only if:
*disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) and
*the company provides filgotinib according to the commercial arrangement.
Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:
*disease is severe (a DAS28 of more than 5.1) and
*they cannot have rituximab and
*the company provides filgotinib according to the commercial arrangement.
Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if:
*disease is severe (a DAS28 of more than 5.1) and
*the company provides filgotinib according to the commercial arrangement.
Filgotinib can be used as monotherapy when methotrexate is contraindicated or if people cannot tolerate it, when the the other criteria listed is met